MONMOUTH JUNCTION, N.J., Oct. 24, 2005 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc. (OTCBB:VQPH) has accepted an invitation to present at the 2005 Medical Innovation Summit: Bench to Bedside and Back, hosted by The Cleveland Clinic on October 24-26th at the InterContinental Hotel & MBNA Conference Center in Cleveland.
Richard Welter, Ph.D., VioQuest's Vice President of Corporate Business Development, will speak on Tuesday, October 25th at 8:20 a.m. CT. Dr. Welter will provide a company overview, including a discussion of VioQuest's two in-licensed oncology compounds, one of which, VQD-001, is currently in Phase I clinical trials at The Cleveland Clinic. VQD-001 is being developed to treat cancer, hepatitis, and infectious diseases.
For the third consecutive year, The Cleveland Clinic will host this international gathering of healthcare movers and shakers to discuss trends in medical innovation. Because The Cleveland Clinic is home to one of the top five orthopedic programs in the country and has been ranked as the nation's top heart center by U.S. News & World Report's annual "America's Best Hospitals" survey eleven years in a row, the Summit promises to deliver a unique perspective on current healthcare trends. The conference is expected to draw more than 800 attendees.
About VioQuest Pharmaceuticals, Inc.
VioQuest Pharmaceuticals, Inc.'s strategy is to acquire, develop, and commercialize targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. The Company is developing two novel anti-cancer agents VQD-001 and VQD-002 for the treatment of melanoma, myeloma, lymphoma; and breast, ovarian, pancreatic, colorectal cancers, respectively. VioQuest's life science subsidiary, Chiral Quest, Inc., a pioneer in asymmetric synthesis, offers proprietary chiral catalysts and synthesis expertise for creating important chiral intermediates and products, which improves the safety, efficacy and manufacturing efficiency of pharmaceutical products. Through Chiral Quest, VioQuest provides products and services to fine chemical manufacturers and twelve of the top eighteen pharmaceutical companies worldwide. For more information please visit www.vioquestpharm.com.
Forward-Looking Statements: This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of VioQuest's research programs and compounds will be successfully commercialized. Risks, uncertainties and assumptions also include the possibility that the market for the sale of certain products may not develop as expected; and that development of these products may not proceed as planned. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2004. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.